Investment Opportunities Under $1,000: DexCom and Stelo

Investors can compound their earnings over time because the stock market tends to climb over time. Two companies worth considering for those looking for companies to buy for less than $1,000 are DexCom and Stelo. DexCom, a diabetes care company, controls approximately 40% of the continuous glucose monitoring (CGM) market. The G7 CGM, launched in 2022, is the company`s fastest and smallest sensor, providing real-time insights for patients. It connects directly to Apple watches in the U.S., Ireland, and the U.K. DexCom also recently received regulatory approval for the first glucose biosensor in the U.S. that doesn`t need a prescription, the Stelo CGM, specifically for type 2 diabetes patients not on insulin therapy.